Updates are available Correction dated 2025-05-13
Click to view Correction: https://doi.org/10.1038/s42255-025-01308-8
-
Authors
Gutgesell, Robert M.
Khalil, Ahmed https://orcid.org/0009-0000-2204-8636
Liskiewicz, Arkadiusz https://orcid.org/0000-0002-4102-5373
Maity-Kumar, Gandhari
Novikoff, Aaron https://orcid.org/0000-0002-4838-001X
Grandl, Gerald https://orcid.org/0000-0003-4456-1988
Liskiewicz, Daniela https://orcid.org/0000-0002-5859-6316
Coupland, Callum https://orcid.org/0000-0001-8921-3616
Karaoglu, Ezgi https://orcid.org/0009-0003-2639-6015
Akindehin, Seun
Castelino, Russell https://orcid.org/0009-0008-7446-6299
Curion, Fabiola
Liu, Xue
Garcia-Caceres, Cristina https://orcid.org/0000-0001-6376-9448
Cebrian-Serrano, Alberto
Douros, Jonathan D.
Knerr, Patrick J.
Finan, Brian
DiMarchi, Richard D. https://orcid.org/0000-0003-0220-4085
Sloop, Kyle W. https://orcid.org/0000-0001-6748-9929
Samms, Ricardo J.
Theis, Fabian J. https://orcid.org/0000-0002-2419-1943
Tschöp, Matthias H. https://orcid.org/0000-0002-4744-371X
Müller, Timo D. https://orcid.org/0000-0002-0624-9339
- License Information
-
More Information
Article History
Received: 17 October 2024
Accepted: 28 March 2025
First Online: 29 April 2025
Change Date: 13 May 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s42255-025-01308-8
Competing interests
: M.H.T. is a member of the scientific advisory board of ERX Pharmaceuticals. He was a member of the Research Cluster Advisory Panel (ReCAP) of the Novo Nordisk Foundation between 2017 and 2019. He attended a scientific advisory board meeting of the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, in 2016. He received funding for his research projects by Novo Nordisk (2016–2020) and Sanofi-Aventis (2012–2019). He was a consultant for Bionorica SE (2013–2017), Menarini Ricerche S.p.A. (2016) and Bayer Pharma AG Berlin (2016). As former Director of the Helmholtz Diabetes Center and the Institute for Diabetes and Obesity at Helmholtz Zentrum München (2011–2018), and since 2018, as CEO of Helmholtz Zentrum München, he has been responsible for collaborations with a multitude of companies and institutions, worldwide. In this capacity, he discussed potential projects with and has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industry and academia, worldwide, including but not limited to pharmaceutical corporations like Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Medigene, Arbormed, BioSyngen and others. In this role, he was/is further responsible for commercial technology transfer activities of his institute(s), including diabetes related patent portfolios of Helmholtz Zentrum München as, for example, WO/2016/188932 A2 or WO/2017/194499 A1. M.H.T. confirms that, to the best of his knowledge, none of the above funding sources were involved in the preparation of this paper. T.D.M. receives research funding by Novo Nordisk and has received speaking fees from Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Merck, AstraZeneca and Mercodia. R.D.D. is a co-inventor on intellectual property owned by Indiana University and licensed to Novo Nordisk. R.D.D., B.F., J.D.D. and P.J.K. were previously employed by Novo Nordisk. B.F., K.W.S. and R.J.S. are current employees of Eli Lilly. The other authors declare no competing interests.
